Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: New concepts in blocking immune suppression

Expert Opinion on Biological Therapy

Volumn 8, Issue 1, 2008, Pages 5-15

  Kretz Rommel, Anke ^a   Bowdish, Katherine S ^a  

^a Aracari Biotech   (United States)

Author keywords

Cancer; CD200; Immune evasion; Immunosuppression; Leukemia; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ALXN 6000; ANTIBODY; CANCER VACCINE; CD200 ANTIBODY; CD200 ANTIGEN; CELL ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; HLA ANTIGEN CLASS 1; RITUXIMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIGENS, CD200; LEUKOCYTE ANTIGEN;

B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; TREATMENT FAILURE; UPREGULATION; ANIMAL; BLOOD DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY;

ANIMALS; ANTIGENS, CD; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 38949208028     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.1.5     Document Type: Review

References (85)

1. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006;103:1041-6
2. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-7
3. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-8
4. Boon T, Coulie PG, Van Den EB. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8
5. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-36
6. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
7. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74
8. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007;13:S727-32
9. Maker AV, Phan GQ, Artia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005;12:1005-16
10. Barclay AN, Ward HA. Purification and chemical characterisation of membrane glycoproteins from rat thymocytes and brain, recognised by monoclonal antibody MRC OX 2. Eur J Biochem 1982;129:447-58
11. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001;102:173-9
12. Clark MJ, Gagnon J, Williams AF, Barclay AN. MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain. EMBO J 1985;4:113-18
13. Barclay AN, Clark MJ, Mccaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986;51:149-57
14. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002;23:285-90
15. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-71
16. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002;161:1669-77
17. Rosenblum MD, Olasz EB, Yancey KB, et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol 2004;123:880-7
18. Gorczynski RM, Chen Z, Yu K, Hu J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol 2001;101:328-34
19. Clark DA, Yu G, Levy GA, Gorczynski RM. Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. Semin Immunol 2001;13:255-63
20. Gorczynski RM. Evidence for an immunoregulatory role of OX2 with its counter ligand (OX2L) in the regulation of transplant rejection, fetal loss, autoimmunity and tumor growth. Arch Immunol Ther Exp (Warsz) 2001;49:303-9
21. Gorczynski RM, Chen Z, Lee L, Yu K, Hu J. Anti-CD20OR ameliorates collagen-induced arthritis in mice. Clin Immunol 2002;104:256-64
22. Copland DA, Calder CJ, Raveney BJ, et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007;171:580-8
23. Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol 2004;78:7667-76
24. Zhang J, Wang J, Wood C, Xu D, Zhang L. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J Virol 2005;79:5640-52
25. Shiratori I, Yamaguchi M, Suzukawa M, et al. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol 2005;175:4441-9
26. Cameron CM, Barrett JW, Liu L, Lucas AR, McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo J Virol 2005;79:6052-67
27. Voigt S, Sandford GR, Hayward GS, Burns WH. The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht. J Gen Virol 2005;86:263-74
28. Langlais CL, Jones JM, Estep RD, Wong SW. Rhesus rhadinovirus R15 encodes a functional homologue of human CD200. J Virol 2006;80:3098-103
29. Gorczynski RM, Cattral MS, Chen Z, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 1999;163:1654-60
30. Ragheb R, Abrahams S, Beecroft R, et al. Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2. Immunol Lett 1999;68:311-15
31. Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L. Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 2004;77:1138-44
32. Fallarino F, Sselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004;173:3748-54
33. +Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:488-91
34. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004;173:6786-93
35. Cherwinski HM, Murphy CA, Joyce BL, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005;174:1348-56
36. Bennett FL, Rawstron AC, O'Connor SJM, et al. Increased expression of CD200 antigen, a potential immunotherapeutic target, is consistently found in CLL cells irrespective of biological features. 108 Edition; 2006
37. Siva A, Xin H, Qin F, et al. Immune evasion by melanoma and ovarian tumor cells through upregulation of the immunosuppressive molecule CD200. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006;24(18S):2545
38. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
39. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81
40. html SEER Stat Fact Sheet on Chronic Lymphocytic Leukaemia Available at: URL: http://seer.cancer.gov/statfacts/html/clyl [last accessed November 2007]
41. Carovsky D. Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2004;18:783-94, vii
42. Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am 2004;18:827-48, viii
43. Mertens D, Wolf S, Schroeter P, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocydc leukemia. Blood 2002;99:4116-21
44. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16
45. Wong KF, So CC. Chronic lymphocytic leukemia with a novel der(8;15)(q10;q10) translocation. Cancer Genet Cytogenet 2002;132:159-60
46. Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003;88:31-8
47. McCaughan GW, Clark MJ, Hurst J, Grosveld F, Barclay AN. The gene for MRC OX-2 membrane glycoprotein is localized on human chromosome 3. Immunogenetics 1987;25:133-5
48. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75
49. Schutz H, Klein SK, Rehwald U, et al. Phase II study of a combined immunochemotherapy using rituximab and fludambine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-20
50. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
51. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
52. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9
53. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62
54. Montserrat E. Role of auto- and allontransplantation in B-cell chronic lymphocytic leukemia. Haematol Oncol Clin North Am 2004;18(4):915-26, x
55. Freedman LR, Cerottini JC, Brunner KT. In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 1972;109:1371-8
56. Bevan MJ, Cohn M. Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 1975;114:559-65
57. Chattopadhyay S, Chakraborty NG. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 2005;66:884-91
58. Tendler CL, Burton JD, Jaffe J, et al. Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 1994;54:4430-5
59. Takeuchi T, Ueki T, Sasaki Y, et al. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 1997;43:375-81
60. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 2000;44:271-4
61. Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002;49:159-66
62. Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 1999;177:203-8
63. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28
64. Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol (In Press)
65. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007;178:5595-605
66. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-91
67. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993;178:661-7
68. Mueller JP, Giannoni MA, Hartman SL, et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 1997;34:441-52
69. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9
70. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65
71. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8
72. Gorczynski RM, Chen Z, Clark DA, et al. Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the fero-maternal interface. Am J Reprod Immunol 2004;52:147-63
73. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966;37:547-59
74. Klein G, Dombos L, Gothoskar B. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer 1972;10:44-57
75. Hami LS, Green C, Leshinsky N, Markham E, Miller K Craig S. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 2004;6:554-62
76. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72
77. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin Exp Immunol 2001;126:16-28
78. Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 2003;9:1656-65
79. Takahashi T, Tanaka Y, Nieda M, et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 2003;27:795-802
80. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 2003;63:4497-506
81. Caligaris-Cappio F, De Leo AM, Bertero MT. Autoimmune phenomena and hepatitis C virus in lymphoproliferative and connective tissue disorders. Leuk Lymphoma 1997;28:57-63
82. Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1689-92
83. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003;30:483-92
84. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patient with chronic lymphocytic leukemia after therapy with fludarabine 2. Blood 2005;106:2018-25
85. Sinkovics JG, Horvath JC. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol 2006;29:765-77